Alfasigma, one of Italy's leading pharmaceutical companies, has agreed to acquire Intercept Pharmaceuticals, a biopharmaceutical company focused on rare and serious liver diseases, for $794 million in a transaction that will expand Alfasigma’s footprint in the United States and strengthen its pipeline.
The pending acquisition will bolster Alfasigma’s portfolio in gastroenterology and hepatology, including the addition of Ocaliva, the only medicine approved by the U.S. Food and Drug Administration for treatment of a progressive autoimmune disease affecting the liver known as primary biliary cholangitis.
The S&C team advising Alfasigma on this cross-border deal was led by Oderisio de Vito Piscicelli, Matt Hurd and Lucas Carsley.
Guiding European Companies in Global Expansions
S&C has long supported Italian and other European companies in their expansion in the United States and other markets, including in the Biopharma industry.
Our multidisciplinary Healthcare & Life Sciences Practice delivers best-in-class services to clients of all sizes, from start-ups to investment funds to the largest global healthcare businesses. We have advised on some of the largest and most innovative cross-border deals, including Seagen in its $43 billion pending acquisition by Pfizer, the largest all-cash pharma takeover in history and the largest-ever all-cash acquisition of a pre-profitability company in any industry; Amgen’s $28.3 billion pending acquisition of Horizon Therapeutics; and Haleon's demerger from GSK and landmark European listing creating the world's biggest stand-alone consumer health company.